| Lena Mullally, DO | |
|
263 Farmington Ave, Farmington, CT 06032-1956 | |
| (860) 679-2839 | |
| Not Available |
| Full Name | Lena Mullally |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 7 Years |
| Location | 263 Farmington Ave, Farmington, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700129558 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 71979 (Connecticut) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospital | Bristol, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charter Anesthesiology Llc | 2163763830 | 37 |
News Archive
The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.
Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."
Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 3 days ago
| Entity Name | Connecticut Gi Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023124625 PECOS PAC ID: 9830110758 Enrollment ID: O20070112000011 |
News Archive
The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.
Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."
Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 3 days ago
| Entity Name | Charter Anesthesiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730674532 PECOS PAC ID: 2163763830 Enrollment ID: O20190520001013 |
News Archive
The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.
Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."
Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lena Mullally, DO 263 Farmington Ave, Farmington, CT 06032-1956 Ph: (860) 679-2839 | Lena Mullally, DO 263 Farmington Ave, Farmington, CT 06032-1956 Ph: (860) 679-2839 |
News Archive
The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.
Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."
Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.
A new study appearing in the journal CHEST®, published by Elsevier, documents an increased incidence of silicosis, which progressed rapidly to massive pulmonary fibrosis in a significant proportion of patients who had previously worked artificial stone (AS), also called artificial quartz agglomerate or conglomerate, a popular new countertop material, despite the cessation of exposure after diagnosis.
› Verified 3 days ago